Australian regenerative medicine company Orthocell (ASX:OCC) has announced the publication of a successful case study focused on the combination of its CelGro collagen medical device with autologous tenocyte implantation (Ortho-ATI) for the surgical repair of a large degenerate tear of the gluteal medius tendon. …
Orthocell updates on world-first case report for its tendon repair treatment
January 28, 2021 Other HealthAustralian Biotech
Latest Video
New Stories
-
Moderna taps Salesforce to unify global commercial operations
April 30, 2026 - - Latest News -
How do we know the HTA institution loves patients? Because they use a love heart emoji
April 30, 2026 - - Latest News -
Australian company secures capital raise to advance amsulostat trials and strengthen pipeline
April 29, 2026 - - Latest News -
Australia urged to strengthen sunscreen literacy and label clarity
April 29, 2026 - -
'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'
April 29, 2026 - - Latest News -
We need to say it again, just in case, that this advice is about ministerial choices and not conditions
April 29, 2026 - - Latest News -
Families welcome cancer drug progress but remain cautious over timely access
April 28, 2026 - - Latest News